失眠治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球失眠治療市場價值為 39 億美元，預計 2025 年至 2034 年期間的複合年成長率為 5.2%。失眠治療涵蓋廣泛的治療方法，旨在幫助患有睡眠障礙的個人，特別是那些難以入睡或保持睡眠的人。由於現代壓力、生活方式的改變和人口老化，全球失眠的盛行率不斷上升，這推動了對有效治療方案的需求。隨著人們越來越意識到睡眠障礙對整體健康的影響，失眠治療市場正在迅速擴大，為製藥公司、醫療保健提供者和數位健康平台提供了巨大的成長機會。

慢性失眠病例的增加推動了藥物開發和替代療法的創新。由於城市化、長時間工作和螢幕時間增加，與壓力相關的睡眠障礙激增，導致對處方藥和非處方藥 (OTC) 的需求增加。失眠認知行為療法（CBT-I）的進步以及人工智慧在睡眠管理解決方案中的整合正在進一步重塑市場。此外，新型失眠治療方法的研究資金和監管部門的批准增加預計將促進市場擴張。對個人化治療計劃和精準醫療的重視也越來越受到關注，從而能夠提供滿足個別患者需求的客製化解決方案。

市場依藥物類別分類，主要包括苯二氮平類藥物、非苯二氮平類藥物、食慾素受體拮抗劑、抗憂鬱劑、抗組織胺、褪黑激素補充劑和其他藥物。 2024 年，苯二氮平類藥物佔據最大的市場佔有率，佔總銷售額的 30.4%。這些藥物被廣泛用於治療與壓力和焦慮相關的失眠，因為它們能有效地減少入睡時間並提高睡眠品質。它們持續受歡迎的原因在於其快速的效果和廣泛的可用性，使它們成為失眠治療的主要選擇。

失眠治療市場依銷售管道進一步細分，處方藥和非處方藥是兩大主要類別。 2024年，處方藥佔市場總銷售額的33.7%。遠距醫療和線上醫療諮詢的興起使得個人更容易得到及時的診斷和適當的治療，從而促進了處方藥銷售的成長。此外，消費者對睡眠不足的健康風險及其與精神健康障礙的關係的認知不斷提高，鼓勵更多人尋求醫療干預。

美國失眠治療市場在 2024 年創造了 16 億美元的產值，預計到 2034 年將達到 26 億美元。領先製藥公司的存在，加上強力的研究計劃和監管支持，正在推動該國市場的成長。美國醫療保健組織持續強調睡眠健康的重要性，並倡導增加研究資金和創新治療方案。 FDA 對新型和改良失眠藥物的批准進一步加速了市場擴張，鞏固了美國在全球失眠治療產業的關鍵地位。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 失眠症盛行率上升
    • 研發進度
    • 人們對睡眠障礙的認知不斷提高
    • 全球老年人口不斷增加
  • 產業陷阱與挑戰
    • 生物製劑和先進療法成本高昂
    • 副作用和依從性問題
• 成長潛力分析
• 監管格局
• 差距分析
• 專利分析
• 管道分析
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按藥物類別，2021 年至 2034 年

• 主要趨勢
• 苯二氮平類
• 非苯二氮平類藥物
• 食慾素受體拮抗劑
• 抗憂鬱藥
• 抗組織胺藥
• 褪黑激素補充劑
• 其他藥物類別

第6章：市場估計與預測：按銷售管道，2021 年至 2034 年

• 主要趨勢
• 非處方藥
• 處方藥

第7章：市場估計與預測：依管理路線，2021 年至 2034 年

• 主要趨勢
• 口服
• 注射劑
• 經皮
• 鼻內

第8章：市場估計與預測：按配銷通路，2021 年至 2034 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 電子商務

第9章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Eisai
• Eli Lilly and Company
• Meiji Seika Pharma
• Merck & Co.
• Neurocrine Biosciences
• Pfizer
• Sanofi
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries
• Vanda Pharmaceuticals
• Woodward Pharma Services

The Global Insomnia Therapeutics Market was valued at USD 3.9 billion in 2024 and is projected to grow at a CAGR of 5.2% between 2025 and 2034. Insomnia therapeutics encompass a broad spectrum of treatments designed to help individuals struggling with sleep disorders, particularly those who have difficulty falling asleep or maintaining sleep. The increasing prevalence of insomnia worldwide, driven by modern-day stressors, shifting lifestyles, and aging populations, is fueling the demand for effective treatment solutions. With growing awareness of the impact of sleep disorders on overall health, the market for insomnia therapeutics is expanding rapidly, providing significant growth opportunities for pharmaceutical companies, healthcare providers, and digital health platforms.

Rising cases of chronic insomnia are propelling innovation in drug development and alternative therapies. Stress-related sleep disorders have surged due to urbanization, long working hours, and increased screen time, leading to a higher demand for prescription and over-the-counter (OTC) medications. Advancements in cognitive behavioral therapy for insomnia (CBT-I) and the integration of artificial intelligence in sleep management solutions are further reshaping the market. Additionally, increased research funding and regulatory approvals for novel insomnia treatments are expected to bolster market expansion. The emphasis on personalized treatment plans and precision medicine is also gaining traction, enabling tailored solutions that cater to individual patient needs.

The market is categorized by drug class, with key segments including benzodiazepines, non-benzodiazepines, orexin receptor antagonists, antidepressants, antihistamines, melatonin supplements, and other medications. Benzodiazepines held the largest share of the market in 2024, accounting for 30.4% of total sales. These drugs are widely prescribed for insomnia associated with stress and anxiety, as they effectively reduce sleep onset time and enhance sleep quality. Their continued popularity stems from their fast-acting results and widespread availability, making them a dominant choice in insomnia treatment.

The insomnia therapeutics market is further segmented by sales channels, with prescription and OTC drugs as the two primary categories. In 2024, prescription drugs accounted for 33.7% of total market sales. The rise of telemedicine and online healthcare consultations has made it easier for individuals to receive timely diagnoses and appropriate treatment, contributing to increased prescription medication sales. Additionally, growing consumer awareness about the health risks of sleep deprivation and its link to mental health disorders has encouraged more individuals to seek medical intervention.

The U.S. Insomnia Therapeutics Market generated USD 1.6 billion in 2024 and is expected to reach USD 2.6 billion by 2034. The presence of leading pharmaceutical companies, coupled with robust research initiatives and regulatory support, is driving market growth in the country. U.S.-based healthcare organizations continue to emphasize the importance of sleep health, advocating for increased research funding and innovative treatment solutions. FDA approvals for new and improved insomnia drugs are further accelerating market expansion, solidifying the U.S. as a key player in the global insomnia therapeutics industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of insomnia
    • 3.2.1.2 Advancements in research and development
    • 3.2.1.3 Growing awareness of sleep disorders
    • 3.2.1.4 Increasing global geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of biologic and advanced therapies
    • 3.2.2.2 Side effects and compliance issues
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Gap analysis
• 3.6 Patent analysis
• 3.7 Pipeline analysis
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Benzodiazepines
• 5.3 Non-benzodiazepine
• 5.4 Orexin receptor antagonists
• 5.5 Antidepressants
• 5.6 Antihistamines
• 5.7 Melatonin supplements
• 5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Sales Channel, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Over-the-counter (OTC) drugs
• 6.3 Prescription drugs

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable
• 7.4 Transdermal
• 7.5 Intranasal

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Eisai
• 10.2 Eli Lilly and Company
• 10.3 Meiji Seika Pharma
• 10.4 Merck & Co.
• 10.5 Neurocrine Biosciences
• 10.6 Pfizer
• 10.7 Sanofi
• 10.8 Takeda Pharmaceutical Company Limited
• 10.9 Teva Pharmaceutical Industries
• 10.10 Vanda Pharmaceuticals
• 10.11 Woodward Pharma Services